The AI entrepreneur fighting against cancer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Selin Kurnaz,  Co-Founder and CEO at Massive Bio,

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Selin, covering:

• How a cancer diagnosis in her family led Selin down a path of accidental entrepreneurship, fundraising, and the application of AI in drug development.
• The major pivots in Massive Bio’s journey that transformed it into a broker of access between patients and pharmaceutical companies.
• Her views on the misallocation of capital in market access enablers versus research and development.
• How gaining traction with advocates inside big pharma helped ensure investors took notice.
• Why the influence of AI on clinical trials and real world evidence will continue to grow as part of the patient journey.

Selin Kurnaz graduated from Boğaziçi University in Turkey, where she had a dual major in industrial engineering and mechanical engineering. She then continued her education in the United States, where she obtained two masters degrees and a doctorate in mechanical engineering at the University of Michigan. Following her education, Selin served as an executive consultant on strategy, operations, and company trading for a decade. In 2015, she co-founded Massive Bio.

Connect with her on LinkedIn.

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!